About Secura Bio
Secura Bio is a Healthcare company based in Henderson (United States) founded in 2018. Consulting services for market access and health outcomes are provided. Secura Bio has raised $55 million across 2 funding rounds from investors including Athyrium Capital Management. Secura Bio offers products and services including COPIKTRA. Its focus areas include Biopharma Outsourcing, Consulting, Business and Market Access & HEOR. Its legal entity is Secura Bio, Inc. Its competitors include Target RWE, STATinMED Research and Hylant.
Company details
Secura Bio was founded in 2018 and is based in Henderson, United States. Services in market access and health outcomes consulting are offered within the pharmaceutical sector. Focus is placed on FARYDAK, a panobinostat capsule capsule utilized for multiple myeloma treatment. Operations emphasize support for drug commercialization and outcomes research in the biotech industry.
- Headquarters Henderson, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website securabio.com
- Social LinkedIn X Facebook Instagram
- Legal Name Secura Bio, Inc
- Total Equity Funding$55M (USD)
in 2 rounds
- Latest Funding Round$55M (USD), Series A
Mar 2019
- Investors
Products & Services of Secura Bio
Secura Bio offers a comprehensive portfolio of products and services, including COPIKTRA.
Medication for treating certain cancers and blood disorders.
Funding Insights of Secura Bio
Secura Bio has successfully raised a total of $55M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $55 million completed in March 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $55M
- Total Rounds 2
- Last Round Series A — $55M
- First Round $50M
(Mar 2019)
- Investors Count 1
All 2 funding rounds of Secura Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2019 | $50M | Debt – Conventional | – | – | |
| Mar 2019 | $55M | Series A | – | Athyrium Capital Management | – |
1 investors in total: 1 institutional.
Investors in Secura Bio
Secura Bio has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | athyrium.com | New York, United States |
Investor details for Secura Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Secura Bio
13 people are tracked at Secura Bio (9 in leadership, 1 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Juan Estruch | Head of Corporate Development | Leadership |
Joseph M. Limber | CEO | Leadership |
Christiane Langer M.D. | Senior Vice President , Head Of Clinical & Medical Affairs | Leadership |
Gregory S. Wessels | VP, Global Marketing | Leadership |
David Sidransky | Clinical & Medical Advisor to the CEO | Leadership |
Cari Barthe | Vice President, Human Resources | Leadership |
Ann Rubbe | Director Of Oncology Marketing & Training | Leadership |
Michelle Bridges | Senior Business Director | Leadership |
Kate Vilaychack-Rizzo | Executive Director Of Global Regulatory Affairs And Clinical Compliance | Leadership |
Jeffrey A. Ferrell | Board Member | Board & advisors |
Patricia Lilagan | Project Manager, Pharmacovigilance | Team |
Miranda Hochstetler | Market Development Manager | Team |
Jamie Sulley | SVP, Global Regulatory Affairs & Technology Operations | Team |
Complete people profiles for Secura Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Secura Bio
2 dated milestones of Secura Bio across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Secura Bio is founded.
- Funding First funding round of $50.0M.
Competitors of Secura Bio
Secura Bio has 3 listed competitors in our database. They include Target RWE, STATinMED Research and Hylant.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| targetrwe.com | 2017 | Durham, United States | 116 | Marketing services to the pharmaceutical industry are provided. | ||
| statinmed.com | 2007 | Ann Arbor, United States | Healthcare data analytics services provider | |||
| hylant.com | 1935 | Toledo, United States | 849 | Offers business insurance, employee benefits, and risk consulting services worldwide. |
Detailed competitors of Secura Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Secura Bio
The website of Secura Bio (securabio.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 60.7% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Secura Bio (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Secura Bio
Complete news archive for Secura Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Secura Bio
Secura Bio was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Secura Bio is headquartered in Henderson, United States. It is registered at Henderson, Nevada, United States.
Secura Bio is a funded company, having raised a total of $55M across 2 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $50M, raised on Mar 2019.
Secura Bio was founded in 2018 and is based in Henderson, United States. Services in market access and health outcomes consulting are offered within the pharmaceutical sector. Focus is placed on FARYDAK, a panobinostat capsule capsule utilized for multiple myeloma treatment. Operations emphasize support for drug commercialization and outcomes research in the biotech industry.
Secura Bio's top competitors include Target RWE, STATinMED Research and Hylant.
Secura Bio offers COPIKTRA.
Secura Bio has 1 investor. Key investors include Athyrium Capital Management.
Secura Bio operates through Secura Bio, Inc.